Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07666815 Creatine monohydrate Chronic Kidney Diseases Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07666815 clinical trial report covering Creatine monohydrate, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Read →
Latest Hotspot
8 min read
NCT07665970 SCTB39G Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07665970 clinical trial report covering SCTB39G, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Read →
Latest Hotspot
8 min read
NCT07664150 CAN016 Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07664150 clinical trial report covering CAN016, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Read →
Latest Hotspot
8 min read
NCT07665684 Albumin-Bound Paclitaxel Mucinous Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07665684 clinical trial report covering Albumin-Bound Paclitaxel, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Read →
Latest Hotspot
8 min read
NCT07665996 Girocitinib Chronic Urticaria Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07665996 clinical trial report covering Girocitinib, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Read →
Latest Hotspot
8 min read
NCT07664696 Isolated, placental, mesenchymal stem cell exosomes(Kimera Labs) COVID-19 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07664696 clinical trial report covering Isolated, placental, mesenchymal stem cell exosomes(Kimera Labs), Phase 1/2, endpoints, sponsor, geography, read
Read →
Latest Hotspot
8 min read
NCT07668960 BBM-C101 Squamous Intraepithelial Lesions of the Cervix Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07668960 clinical trial report covering BBM-C101, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Read →
Latest Hotspot
8 min read
NCT07668284 Ubidecarenone Prostatic Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07668284 clinical trial report covering Ubidecarenone, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Read →
Latest Hotspot
8 min read
NCT07668518 Phosphoinositide 3-kinase Gamma Peptide Pulmonary Disease, Chronic Obstructive Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07668518 clinical trial report covering Phosphoinositide 3-kinase Gamma Peptide, Phase 1/2, endpoints, sponsor, geography, readout timing and developmen
Read →
Latest Hotspot
8 min read
NCT07667400 Docetaxel Hypopharyngeal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07667400 clinical trial report covering Docetaxel, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Read →
Latest Hotspot
8 min read
NCT07667335 Quemliclustat Ureteral Neoplasms Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07667335 clinical trial report covering Quemliclustat, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Read →
Latest Hotspot
8 min read
NCT07670312 XYA-02 Pancreatic adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07670312 clinical trial report covering XYA-02, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Read →
<
1
<<
997
998
999
1000
1001
>>
2260
>